Last reviewed · How we verify
NCT06085378: TK-SEEK
Efficacy and Safety of Urinary Kallidinogenase in the Treatment of Acute Ischemic Stroke Combined With Type 2 Diabetes Mellitus
NA trial testing Urinary Kallidinogenase for injection in Acute Ischemic Stroke in 630 participants. Not yet recruiting.
31 December 2026
Quick facts
| Lead sponsor | First Affiliated Hospital, Sun Yat-Sen University |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 630 |
| Start date | 1 January 2024 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Urinary Kallidinogenase for injection — full drug profile →
- Placebo
Conditions studied
- Acute Ischemic Stroke — all drugs for Acute Ischemic Stroke →
- Type 2 Diabetes — all drugs for Type 2 Diabetes →
Sponsor
First Affiliated Hospital, Sun Yat-Sen University
Who can join
Adults 18 to 80, any sex, with Acute Ischemic Stroke or Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a multicenter, randomized, double-blind, placebo parallel control study, aim to evaluate the efficacy and safety of human urinary kallidinogenase in the treatment of acute ischemic stroke with type 2 diabetes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06085378
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Ischemic Stroke
Currently open trials in the same condition.
- NCT07115940 — Medical Management With Endovascular Thrombectomy Versus Medical Management Alone in Patients Presenting Beyond 24 Hours · NA · recruiting
- NCT07404852 — Non-invasive Vagus Nerve Stimulation to Reduce Inflammation and Brain Injury Blood Biomarkers Following an Acute Ischemi · NA · recruiting
- NCT07361302 — A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Pe · Phase 3 · recruiting
- NCT07436156 — SUMMIT RISE Study of Acute Ischemic Stroke Patients · Phase 4 · recruiting
- NCT07203625 — Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 Hours · Phase 4 · recruiting
Other First Affiliated Hospital, Sun Yat-Sen University trials
Trials by the same sponsor.
- NCT07322835 — Efficacy and Safety of Reperfusion Therapy for Minor Ischemic Stroke in China · not yet recruiting
- NCT07322848 — DEB-TACE vs cTACE in HCC After TIPS · Phase 3 · recruiting
- NCT07087418 — AI-Driven Multimodal Imaging Integration for Diagnosis and Prognostication of Digestive System Diseases · recruiting
- NCT07014475 — Efficacy of the Ranger Drug-Coated Balloon in Treating BTK Lesions in Patients With CLTI · not yet recruiting
- NCT06951334 — Clinical Trial of Vildagliptin in Early Parkinson's Disease · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06085378 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital, Sun Yat-Sen University
- Last refreshed: 16 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06085378.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing